A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease
This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in participants with manifest Huntington's disease (HD)
Inclusion Criteria:
Exclusion Criteria:
Washington D.C., District of Columbia 20007, United States
Houston, Texas 77030, United States
CABA, C1221ADC, Argentina
Capital Federal, C1192AAX, Argentina
Ciudad Autonoma Buenos Aires, C1284AEB, Argentina
Innsbruck, 6020, Austria
Salzburg, 5020, Austria
Vancouver, British Columbia V6T 2B5, Canada
North YORK, Ontario M3B 2S7, Canada
Berlin, 10117, Germany
Bochum, 44791, Germany
Lübeck, 23538, Germany
San Giovanni Rotondo, Apulia 71013, Italy
Bologna, Emilia-Romagna 40139, Italy
Milan, Lombardy 20133, Italy
Okayama, 700-8558, Japan
Krasnoyarsk, Krasnoyarsk Krai 660037, Russia
Moskva, Moscow Oblast 125367, Russia
Kazan', Tatarstan Republic 420061, Russia
Cambridge, CB2 0SP, United Kingdom
Cardiff, CF14 4XW, United Kingdom
Manchester, M13 9WL, United Kingdom
Southhampton, SO16 6YD, United Kingdom